Phase 2 Colorectal Cancer Trial, Recruiting (NCT06440902)

Phase 2 Colorectal Cancer Trial, Recruiting NCT06440902 Sponsor: Fudan University Condition: Colorectal Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06440902 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Colorectal Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with colorectal cancer that has spread to other parts of the body (metastatic), and testing has shown a specific gene change called a RAS mutation in your tumour
You are generally well enough to carry out light activity and care for yourself (rated 0 or 1 on a standard health scale used by doctors)
You are willing and able to give your written agreement to take part in the trial
A sample of tumour tissue (from surgery or a needle biopsy) can be collected, and a small blood sample of about 10ml can be taken

Who may not be able to join:

Your colorectal cancer diagnosis has not been confirmed through a colonoscopy biopsy or a biopsy of a site where the cancer has spread
Your colorectal cancer has not spread beyond the original area (classified as stage I, II, or III rather than stage IV/metastatic)
Testing has shown that your cancer does NOT have a RAS mutation (known as "RAS wild-type")
Your blood, liver, or kidney function is not working well enough (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 5 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Junjie Peng, PhD, Fudan University

Phone: +86 13917373312

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06440902

Sponsor: Fudan University

Phase: Phase 2

Status: Recruiting

Condition: Colorectal Cancer

Trial contact: +86 13917373312

More information: https://clinicaltrials.gov/study/NCT06440902

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with colorectal cancer that has spread to other parts of the body (metastatic), and testing has shown a specific gene change called a RAS mutation in your tumour
You are generally well enough to carry out light activity and care for yourself (rated 0 or 1 on a standard health scale used by doctors)
You are willing and able to give your written agreement to take part in the trial
A sample of tumour tissue (from surgery or a needle biopsy) can be collected, and a small blood sample of about 10ml can be taken

Who may not be able to join:

Your colorectal cancer diagnosis has not been confirmed through a colonoscopy biopsy or a biopsy of a site where the cancer has spread
Your colorectal cancer has not spread beyond the original area (classified as stage I, II, or III rather than stage IV/metastatic)
Testing has shown that your cancer does NOT have a RAS mutation (known as "RAS wild-type")
Your blood, liver, or kidney function is not working well enough (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 5 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Fudan University

Registry

ClinicalTrials.gov

Start date

28 December 2023

Est. completion

1 September 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Detection rate of NeoRAS WT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov